WO2008090198A1 - Use of mtp inhibitors for increasing levels of satiety hormones - Google Patents
Use of mtp inhibitors for increasing levels of satiety hormones Download PDFInfo
- Publication number
- WO2008090198A1 WO2008090198A1 PCT/EP2008/050814 EP2008050814W WO2008090198A1 WO 2008090198 A1 WO2008090198 A1 WO 2008090198A1 EP 2008050814 W EP2008050814 W EP 2008050814W WO 2008090198 A1 WO2008090198 A1 WO 2008090198A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cck
- phenyl
- satiety
- levels
- trifluoromethyl
- Prior art date
Links
- 229940088597 hormone Drugs 0.000 title claims abstract description 28
- 239000005556 hormone Substances 0.000 title claims abstract description 28
- 230000036186 satiety Effects 0.000 title claims abstract description 26
- 235000019627 satiety Nutrition 0.000 title claims abstract description 26
- 239000003112 inhibitor Substances 0.000 title abstract description 9
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims abstract description 19
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims abstract description 19
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims abstract 5
- 150000001875 compounds Chemical class 0.000 claims description 20
- 230000002401 inhibitory effect Effects 0.000 claims description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 206010022489 Insulin Resistance Diseases 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- TUOSYWCFRFNJBS-BHVANESWSA-N dirlotapide Chemical compound O=C([C@@H](NC(=O)C=1N(C2=CC=C(NC(=O)C=3C(=CC=CC=3)C=3C=CC(=CC=3)C(F)(F)F)C=C2C=1)C)C=1C=CC=CC=1)N(C)CC1=CC=CC=C1 TUOSYWCFRFNJBS-BHVANESWSA-N 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- WSYALRNYQFNNGP-UHFFFAOYSA-N methyl 2-phenyl-2-[4-[4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]phenyl]piperidin-1-yl]acetate Chemical compound C=1C=CC=CC=1C(C(=O)OC)N(CC1)CCC1C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1C1=CC=C(C(F)(F)F)C=C1 WSYALRNYQFNNGP-UHFFFAOYSA-N 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 3
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 229960002551 dirlotapide Drugs 0.000 claims description 2
- HCPOCMMGKBZWSJ-UHFFFAOYSA-N ethyl 3-hydrazinyl-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)NN HCPOCMMGKBZWSJ-UHFFFAOYSA-N 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- JKHYOWBRQRJSTQ-OAQYLSRUSA-N methyl n-[(2r)-5-[[3-methyl-2-[4-(trifluoromethyl)phenyl]benzoyl]amino]-2,3-dihydro-1h-inden-2-yl]carbamate Chemical compound C([C@H](CC1=C2)NC(=O)OC)C1=CC=C2NC(=O)C1=CC=CC(C)=C1C1=CC=C(C(F)(F)F)C=C1 JKHYOWBRQRJSTQ-OAQYLSRUSA-N 0.000 claims description 2
- 208000027232 peripheral nervous system disease Diseases 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims 3
- ZPCAVCLHZWOBRW-UHFFFAOYSA-N n-[2-(2-pyrazol-1-ylacetyl)-1,3-dihydroisoindol-5-yl]-2-[5-(trifluoromethyl)pyridin-2-yl]benzamide Chemical compound N1=CC(C(F)(F)F)=CC=C1C1=CC=CC=C1C(=O)NC1=CC=C(CN(C2)C(=O)CN3N=CC=C3)C2=C1 ZPCAVCLHZWOBRW-UHFFFAOYSA-N 0.000 claims 1
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 abstract description 28
- 108010038232 microsomal triglyceride transfer protein Proteins 0.000 abstract description 28
- 230000036470 plasma concentration Effects 0.000 abstract description 7
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 description 15
- 108010088847 Peptide YY Proteins 0.000 description 15
- 102100029909 Peptide YY Human genes 0.000 description 15
- 102100040918 Pro-glucagon Human genes 0.000 description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 230000037213 diet Effects 0.000 description 13
- 235000005911 diet Nutrition 0.000 description 13
- 210000002381 plasma Anatomy 0.000 description 13
- 229940126062 Compound A Drugs 0.000 description 11
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 11
- 235000012054 meals Nutrition 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 7
- 235000013305 food Nutrition 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000000291 postprandial effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 3
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 101800001982 Cholecystokinin Proteins 0.000 description 2
- 108010004103 Chylomicrons Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- -1 cholesteryl ester Chemical class 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000003629 gastrointestinal hormone Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- IVCOLVXXCVGZJW-CCPSMLFMSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1-oxo-3-(4-sulfooxyphenyl)propan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccc(OS(O)(=O)=O)cc1)C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O IVCOLVXXCVGZJW-CCPSMLFMSA-N 0.000 description 1
- QQQSLUJJBRKRHP-UHFFFAOYSA-N 1-[[3-methoxy-2-[4-(trifluoromethyl)phenyl]benzoyl]amino]-3,4-dihydro-1h-isoquinoline-2-carboxylic acid Chemical compound COC1=CC=CC(C(=O)NC2C3=CC=CC=C3CCN2C(O)=O)=C1C1=CC=C(C(F)(F)F)C=C1 QQQSLUJJBRKRHP-UHFFFAOYSA-N 0.000 description 1
- HQSRVYUCBOCBLY-XOOFNSLWSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2s,4r)-2-(4-chlorophenyl)-2-[(4-methyl-1,2,4-triazol-3-yl)sulfanylmethyl]-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3O[C@@](CSC=4N(C=NN=4)C)(OC3)C=3C=CC(Cl)=CC=3)=CC=2)C=C1 HQSRVYUCBOCBLY-XOOFNSLWSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 101800001099 Cholecystokinin-39 Proteins 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 1
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000009956 central mechanism Effects 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- QFLBZJPOIZFFJQ-UHFFFAOYSA-N cholecystokinin 33 Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CCSC)C(=O)NC(CC(O)=O)C(=O)NC(CC=1C=CC=CC=1)C(N)=O)NC(=O)CNC(=O)C(CCSC)NC(=O)C(C=1C=CC(OS(O)(=O)=O)=CC=1)NC(=O)C(CC(O)=O)NC(=O)C(CCCNC(N)=N)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(C(C)CC)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(CO)NC(=O)C1N(CCC1)C(=O)C(CC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(CC(N)=O)NC(=O)C(CCCCN)NC(=O)C(NC(=O)C(NC(=O)C(CO)NC(=O)C(CCSC)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(CO)NC(=O)C1N(CCC1)C(=O)C(C)NC(=O)C(N)CCCCN)C(C)CC)C(C)C)CC1=CNC=N1 QFLBZJPOIZFFJQ-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- FPUQGCOBYOXAED-UHFFFAOYSA-N diethyl 2-[[2-[3-(dimethylcarbamoyl)-4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]phenyl]acetyl]oxymethyl]-2-phenylpropanedioate Chemical compound C=1C=CC=CC=1C(C(=O)OCC)(C(=O)OCC)COC(=O)CC(C=C1C(=O)N(C)C)=CC=C1NC(=O)C1=CC=CC=C1C1=CC=C(C(F)(F)F)C=C1 FPUQGCOBYOXAED-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- MBBCVAKAJPKAKM-UHFFFAOYSA-N lomitapide Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1(C(=O)NCC(F)(F)F)CCCCN(CC1)CCC1NC(=O)C1=CC=CC=C1C1=CC=C(C(F)(F)F)C=C1 MBBCVAKAJPKAKM-UHFFFAOYSA-N 0.000 description 1
- 229960003566 lomitapide Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229950000884 mitratapide Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000010004 neural pathway Effects 0.000 description 1
- 210000000118 neural pathway Anatomy 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 201000005572 sensory peripheral neuropathy Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to the use of inhibitors of microsomal triglyceride transfer protein (MTP) for increasing plasma levels of the satiety hormones such as GLP-1 , PYY and CCK.
- MTP microsomal triglyceride transfer protein
- Microsomal triglyceride transfer protein (hereinafter referred to as MTP) is known to catalyze the transport of triglyceride, cholesteryl ester and phospholipids such as phosphatidylcholine. This indicates that MTP is required for the synthesis of Apo B-containing lipoproteins such as chylomicrons and VLDL, the precursor to LDL. It therefore follows that an MTP inhibitor would inhibit the synthesis of VLDL and chylomicrons, thereby lowering levels of VLDL, LDL, cholesterol and triglyceride in humans.
- MTP Microsomal triglyceride transfer protein
- Compounds capable of inhibiting MTP are believed to be useful in the treatment of disorders such as obesity, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, class Il diabetes, atherosclerosis and for the reduction of postprandial serum triglyceride plasma levels.
- Satiety hormones are hormones released from the gastrointestinal tract in response to changes in the nutritional state. These hormones influence central mechanisms involved in the regulation of energy balance, through a range of bloodborne and neural pathways.
- Glucagon-like peptide 1 is an intestinal hormone which generally stimulates insulin secretion during hyperglycemia, suppresses glucagon secretion, stimulates (pro) insulin biosynthesis and decelerates gastric emptying and acid secretion.
- GLP-1 is secreted from L cells in the small and large bowel following the ingestion of fat and proteins. GLP-1 has been implicated as a possible therapeutic agent for the management of type 2 non-insulin-dependent diabetes mellitus as well as related metabolic disorders, such as obesity.
- Pancreatic polypeptide (“PP") was discovered as a contaminant of insulin extracts and was named by its organ of origin rather than functional importance.
- a related peptide was subsequently discovered in extracts of intestine and named Peptide YY ("PYY") because of the N- and C-terminated tyrosines (Tatemoto, Proc. Natl. Acad. Sci. USA, 79 : 2514 -2518 (1982)).
- PYY is secreted from the endocrine L cells of the small and large bowel, with high concentration at the terminal ileum, colon and maximum concentration in the rectum. Plasma PYY levels are suppressed in the fasted state and increase within 30 minutes of nutrients reaching the gut.
- PYY release is stimulated by nutrient intake in proportion to energy content. It is particularly stimulated by fat intake, compared to carbohydrate and protein meals with a similar calorie content. Recent studies suggest that PYY can induce appetite reduction.
- CCK Cholecystokinin is structurally related to gastrin and exists in several molecular forms with differing numbers of amino acids - examples include CCK-8, CCK-33, CCk-39 and CCK-54.
- CCK is an endogenous gut hormone found mainly within the duodenum and jejunum and is released following the consumption of food. Release of CCK has been shown to be a satiety signal in humans.
- CCK releasing protein CCKRP
- CCKRP stimulates CCK release from the intestinal cells. It has been shown that CCK release results in appetite reduction so that the person will stop eating.
- CCK satiety hormone
- An increase in the level of the satiety hormone CCK extends the feeling of satiety, resulting in a decrease of food intake which over time results in a decrease in body weight while providing better regulation of glucose and insulin levels following consumption of a meal.
- the release of CCK also causes a delay in stomach emptying which blunts the post-prandial rise in glucose and insulin.
- Most persons with Type Il diabetes are obese and have an inability to respond normally to insulin.
- An increase in CCK levels may permit Type Il diabetics to be satiated with a lower caloric intake and may offer a better degree of glycemic control.
- Bulimia is an eating disorder characterised by an inability to become satiated by food. As a result bulimics tend to binge on food and regurgitate it to prevent weight gain. Studies have shown that bulimics have a defect in their normal satiety mechanism. Hence an increase of the satiety hormones would permit bulimics to feel satiated.
- MTP microsomal triglyceride transfer protein
- the present invention provides a method for increasing the levels of satiety hormones, in particular GLP-1 , PYY and CCK, in a mammalian subject, which method comprises administering to a mammal a therapeutically effective amount of an MTP inhibiting compound or a pharmaceutical composition comprising a MTP inhibiting compound.
- MTP inhibiting compound for increasing the levels of satiety hormones, in particular the GLP-1 , PYY and CCK hormones, also has a lowering effect on the level of glucose in blood plasma and increases insulin sensitivity.
- Insulin resistance is the condition in which normal amounts of insulin are inadequate to produce a normal insulin response from fat, muscle and liver cells. Insulin resistance in fat cells results in hydrolysis of stored triglycerides, which elevates free fatty acids in the blood plasma. Insulin resistance in muscle reduces glucose uptake whereas insulin resistance in liver reduces glucose storage, with both effects serving to elevate blood glucose. High plasma levels of insulin and glucose due to insulin resistance often leads to the metabolic syndrome and type 2 diabetes.
- the present invention also relates to the use of MTP inhibiting compounds for increasing the levels of the satiety hormone GLP-1 for the treatment of cardiomyopathy.
- the present invention also relates to the use of MTP inhibiting compounds for increasing the levels of the satiety hormone GLP-1 for the treatment of peripheral neuropathies.
- MTP inhibiting compounds have been disclosed in, e.g., Janssen Pharmaceutica : WO-96/13499, WO-02/20501 , WO-02/42271 , WO-02/081460, WO-2005/058824, and WO-2005/085226; Bristol-Myers-Squibb : EP-0,584,446, EP-0,643,057, WO-96/26205, WO-97/26240, WO-91/43255, WO-97/43257, WO-98/27979, and WO-99/21564; GSK : WO-98/16526, WO-98/47877,
- WO-98/56790 WO-00/32582, WO-01/92241 , WO-01/96327, and WO-03/048121 ; Japan Tobacco : WO-99/31085, WO-03/072532, and WO-2006/008962; Meji Seika Kaisho : WO-98/54135; Novartis : WO-01/77077 and WO-2000/005201 ; Pfizer : WO-96/40640, and WO-98/23593.
- MTP inhibiting compounds are, e.g., dirlotapide or (S)-N- ⁇ 2- [benzyl(methyl)amino]-2-oxo-1 -phenylethyl ⁇ -1 -methyl-5-[4'-(trifluoromethyl)[1 , 1 '- biphenyl]-2-carboxamido]-1 H-indole-2-carboxamide; BMS201038 or N-(2,2,2- trifluoroethyl)-9-[4-[4-[[(4'-trifluoromethyl)-1 ,1 '-biphenyl-2-yl]carbonyl]amino)-1- piperidinyl]butyl]-9H-fluorene-9-carboxamide (EP-0,643,057); mitratapide or (-)-[2S- [2 ⁇ ,4 ⁇ (S * )]]-4-[4-[4-[4-[[2-(4-chloropheny
- mamal or “mammalian subject” refers to human and non- human patients.
- a "therapeutically effective amount" of a MTP inhibiting compound is the quantity of a compound which, when administered to a mammalian subject, results in a sufficiently high level of that MTP inhibiting compound in the mammalian to cause a discernible increase of the blood plasma levels of the satiety hormones GLP-1 , PYY and CCK.
- compositions comprising a MTP inhibiting compound can be administered to a subject either orally, parenterally (for example intravenously, intramuscularly or subcutaneously), percutaneously, or rectally.
- Solid dosage forms for oral administration include capsules, dragees, tablets, powders and granules. These solid dosage forms are preferably formulated in dosage unit form for ease of administration and uniformity of dosage.
- dosage unit form refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined amount of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, suspo-emulsions, syrups and elixirs.
- Pharmaceutical compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspension, or emulsions, or may comprise sterile powders for reconstitution into sterile injectable solutions or dispersions.
- Figure 1 is a graph displaying plasma CCK (pMol/l) expressed as the median value per group just before the meal and 12 and 24 hours after the meal.
- Figure 2 is a graph displaying the postprandial plasma PYY (pMol/l) levels after 0.02% (w/w) administration of the MTP inhibitor "compound A" mixed in diet containing 17.5% (w/w) (35 kcal%) fat.
- Figure 3 is a graph displaying the postprandial plasma GLP-1 (pg/l) levels after 0.02% (w/w) administration of the MTP inhibitor "compound A" mixed in diet containing 17.5% (w/w) (35 kcal%) fat.
- the treatment groups were :
- Rats Male Sprauge-Dawley rats (Iffa-Credo) are housed in individually ventilated cages under controlled temperature (20-24 0 C), humidity (45-65%) and light (12-12h light/dark cycle; Lights on - 5 AM - 5PM). Rats were adapted to a semipurified casein, cornstarch and sucrose based diet (AIN-93) containing 17.5% w/w corn oil as the fat source for 10 days. The 17.5% diet is calculated to contain 35% of energy as fat.
- Rats Male Sprauge-Dawley rats (Iffa-Credo) are housed in individually ventilated cages under controlled temperature (20-24 0 C), humidity (45-65%) and light (12-12h light/dark cycle; Lights on - 5 AM - 5PM). Rats were adapted to a semipurified casein, cornstarch and sucrose based diet (AIN-93) containing 17.5% w/w corn oil as the fat source for 10 days. The 17.5% diet is calculated to contain 35% of energy as fat.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to the use of inhibitors of microsomal triglyceride transfer protein (MTP) for increasing plasma levels of the satiety hormones such as GLP-1, PYY and CCK.
Description
USE OF MTP INHIBITORS FOR INCREASING LEVELS OF SATIETY HORMONES
[0001] The present invention relates to the use of inhibitors of microsomal triglyceride transfer protein (MTP) for increasing plasma levels of the satiety hormones such as GLP-1 , PYY and CCK.
[0002] Microsomal triglyceride transfer protein (hereinafter referred to as MTP) is known to catalyze the transport of triglyceride, cholesteryl ester and phospholipids such as phosphatidylcholine. This indicates that MTP is required for the synthesis of Apo B-containing lipoproteins such as chylomicrons and VLDL, the precursor to LDL. It therefore follows that an MTP inhibitor would inhibit the synthesis of VLDL and chylomicrons, thereby lowering levels of VLDL, LDL, cholesterol and triglyceride in humans. Compounds capable of inhibiting MTP are believed to be useful in the treatment of disorders such as obesity, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, class Il diabetes, atherosclerosis and for the reduction of postprandial serum triglyceride plasma levels.
[0003] Satiety hormones are hormones released from the gastrointestinal tract in response to changes in the nutritional state. These hormones influence central mechanisms involved in the regulation of energy balance, through a range of bloodborne and neural pathways.
[0004] Glucagon-like peptide 1 (GLP-1 ) is an intestinal hormone which generally stimulates insulin secretion during hyperglycemia, suppresses glucagon secretion, stimulates (pro) insulin biosynthesis and decelerates gastric emptying and acid secretion. GLP-1 is secreted from L cells in the small and large bowel following the ingestion of fat and proteins. GLP-1 has been implicated as a possible therapeutic agent for the management of type 2 non-insulin-dependent diabetes mellitus as well as related metabolic disorders, such as obesity.
[0005] Pancreatic polypeptide ("PP") was discovered as a contaminant of insulin extracts and was named by its organ of origin rather than functional importance. A related peptide was subsequently discovered in extracts of intestine and named Peptide YY ("PYY") because of the N- and C-terminated tyrosines (Tatemoto, Proc. Natl. Acad. Sci. USA, 79 : 2514 -2518 (1982)). PYY is secreted from the endocrine L cells of the small and large bowel, with high concentration at the terminal ileum, colon and maximum concentration in the rectum. Plasma PYY levels are suppressed in the
fasted state and increase within 30 minutes of nutrients reaching the gut. PYY release is stimulated by nutrient intake in proportion to energy content. It is particularly stimulated by fat intake, compared to carbohydrate and protein meals with a similar calorie content. Recent studies suggest that PYY can induce appetite reduction.
[0006] Cholecystokinin is structurally related to gastrin and exists in several molecular forms with differing numbers of amino acids - examples include CCK-8, CCK-33, CCk-39 and CCK-54. CCK is an endogenous gut hormone found mainly within the duodenum and jejunum and is released following the consumption of food. Release of CCK has been shown to be a satiety signal in humans. When food is consumed, CCK releasing protein (CCKRP) is released in the small intestine. CCKRP stimulates CCK release from the intestinal cells. It has been shown that CCK release results in appetite reduction so that the person will stop eating.
[0007] The ability of CCK to reduce appetite appears to make it a useful agent in the treatment of obesity. An increase in the level of the satiety hormone CCK would result in less food consumed and reduction of hunger cravings between meals. These effects would enable an overweight individual to better comply with a diet that has a reduced caloric intake.
[0008] An increase in the level of the satiety hormone CCK extends the feeling of satiety, resulting in a decrease of food intake which over time results in a decrease in body weight while providing better regulation of glucose and insulin levels following consumption of a meal. The release of CCK also causes a delay in stomach emptying which blunts the post-prandial rise in glucose and insulin. Most persons with Type Il diabetes are obese and have an inability to respond normally to insulin. An increase in CCK levels may permit Type Il diabetics to be satiated with a lower caloric intake and may offer a better degree of glycemic control.
[0009] Bulimia is an eating disorder characterised by an inability to become satiated by food. As a result bulimics tend to binge on food and regurgitate it to prevent weight gain. Studies have shown that bulimics have a defect in their normal satiety mechanism. Hence an increase of the satiety hormones would permit bulimics to feel satiated.
[0010] Unexpectedly it has now been observed that when inhibitors of microsomal triglyceride transfer protein (MTP) are administered to a mammalian subject, the plasma levels of the satiety hormones such as GLP-1 , PYY and CCK are increased.
[0011] The present invention provides the use of a MTP inhibiting compound for the manufacture of a medicament for increasing the levels of satiety hormones, such as the GLP-1 , PYY and CCK hormones. Also provided is the use of a pharmaceutical composition comprising a MTP inhibiting compound for the manufacture of a medicament for increasing the levels of satiety hormones, such as the GLP-1 , PYY and CCK hormones.
[0012] Further, the present invention provides a method for increasing the levels of satiety hormones, in particular GLP-1 , PYY and CCK, in a mammalian subject, which method comprises administering to a mammal a therapeutically effective amount of an MTP inhibiting compound or a pharmaceutical composition comprising a MTP inhibiting compound.
[0013] The use of MTP inhibiting compound for increasing the levels of satiety hormones, in particular the GLP-1 , PYY and CCK hormones, also has a lowering effect on the level of glucose in blood plasma and increases insulin sensitivity. Insulin resistance is the condition in which normal amounts of insulin are inadequate to produce a normal insulin response from fat, muscle and liver cells. Insulin resistance in fat cells results in hydrolysis of stored triglycerides, which elevates free fatty acids in the blood plasma. Insulin resistance in muscle reduces glucose uptake whereas insulin resistance in liver reduces glucose storage, with both effects serving to elevate blood glucose. High plasma levels of insulin and glucose due to insulin resistance often leads to the metabolic syndrome and type 2 diabetes.
[0014] Studies in dogs with an induced dilated cardiomyopathy have shown that a 48 hour of GLP-1 infusion improved the left ventricular function, and reduced systemic vascular resistance compared with saline-treated control animals (Nikolaidis LA et al., Circulation 2004; 110:955-961 ). Accordingly the present invention also relates to the use of MTP inhibiting compounds for increasing the levels of the satiety hormone GLP-1 for the treatment of cardiomyopathy.
[0015] Studies in rats with pyridoxine induced peripheral sensory neuropathy suggest neuroprotection mediated by agonism at the GLP-1 receptor (Perry T. et al, Experimental Neurology 2007:203, 293 - 301 ). Accordingly the present invention also relates to the use of MTP inhibiting compounds for increasing the levels of the satiety hormone GLP-1 for the treatment of peripheral neuropathies.
- A -
[0016] MTP inhibiting compounds have been disclosed in, e.g., Janssen Pharmaceutica : WO-96/13499, WO-02/20501 , WO-02/42271 , WO-02/081460, WO-2005/058824, and WO-2005/085226; Bristol-Myers-Squibb : EP-0,584,446, EP-0,643,057, WO-96/26205, WO-97/26240, WO-91/43255, WO-97/43257, WO-98/27979, and WO-99/21564; GSK : WO-98/16526, WO-98/47877,
WO-98/56790, WO-00/32582, WO-01/92241 , WO-01/96327, and WO-03/048121 ; Japan Tobacco : WO-99/31085, WO-03/072532, and WO-2006/008962; Meji Seika Kaisho : WO-98/54135; Novartis : WO-01/77077 and WO-2000/005201 ; Pfizer : WO-96/40640, and WO-98/23593.
[0017] Particular MTP inhibiting compounds are, e.g., dirlotapide or (S)-N-{2- [benzyl(methyl)amino]-2-oxo-1 -phenylethyl}-1 -methyl-5-[4'-(trifluoromethyl)[1 , 1 '- biphenyl]-2-carboxamido]-1 H-indole-2-carboxamide; BMS201038 or N-(2,2,2- trifluoroethyl)-9-[4-[4-[[(4'-trifluoromethyl)-1 ,1 '-biphenyl-2-yl]carbonyl]amino)-1- piperidinyl]butyl]-9H-fluorene-9-carboxamide (EP-0,643,057); mitratapide or (-)-[2S- [2α,4α(S*)]]-4-[4-[4-[4-[[2-(4-chlorophenyl)-2-[[(4-methyl-4H-1 ,2,4-triazol-3- yl)thio]methyl]-1 ,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2- (1 -methylpropyl)-3H-1 ,2,4-triazol-3-one (WO-96/13499); (+)-phenyl-(4-{4-[(4'- trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-piperidin-1 -yl)-acetic acid methyl ester (WO-02/20501 ); JTT-130 or diethyl ester[[[[3-[(dimethylamino)carbonyl]-4-[[[4'- (trifluoromethylXI J '-biphenylj^-yljcarbonyljaminojphenyljacetyljoxyjmethyljphenyl propanedioic acid (WO-2006/008962); SLx 4090 from Surface Logix; NA-2003 from Meiji Seika Kaisha; [(2R)-2,3-dihydro-5-[[[6-methyl-4'-(trifluoromethyl)[1 ,1 '-biphenyl]-2- yl]carbonyl]amino]-1 H-inden-2-yl]-carbamic acid methyl ester (WO-2000/005201 ); T-0126 or N-[2-[2-(1 H-Pyrazol-1-yl)acetyl]-2,3-dihydro-1 H-isoindol-5-yl]-2-[5-
(trifluoromethyl)pyridin-2-yl]benzamide from Tanabe Seiyaku (WO-2002/014276).
[0018] As used herein, "mammal" or "mammalian subject" refers to human and non- human patients.
[0019] As used herein, a "therapeutically effective amount" of a MTP inhibiting compound, is the quantity of a compound which, when administered to a mammalian subject, results in a sufficiently high level of that MTP inhibiting compound in the mammalian to cause a discernible increase of the blood plasma levels of the satiety
hormones GLP-1 , PYY and CCK.
[0020] The pharmaceutical compositions comprising a MTP inhibiting compound can be administered to a subject either orally, parenterally (for example intravenously, intramuscularly or subcutaneously), percutaneously, or rectally.
[0021] Solid dosage forms for oral administration include capsules, dragees, tablets, powders and granules. These solid dosage forms are preferably formulated in dosage unit form for ease of administration and uniformity of dosage. "Dosage unit form" as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined amount of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.
[0022] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, suspo-emulsions, syrups and elixirs. Pharmaceutical compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspension, or emulsions, or may comprise sterile powders for reconstitution into sterile injectable solutions or dispersions.
Description of the drawings [0023] Figure 1 is a graph displaying plasma CCK (pMol/l) expressed as the median value per group just before the meal and 12 and 24 hours after the meal.
[0024] Figure 2 is a graph displaying the postprandial plasma PYY (pMol/l) levels after 0.02% (w/w) administration of the MTP inhibitor "compound A" mixed in diet containing 17.5% (w/w) (35 kcal%) fat.
[0025] Figure 3 is a graph displaying the postprandial plasma GLP-1 (pg/l) levels after 0.02% (w/w) administration of the MTP inhibitor "compound A" mixed in diet containing 17.5% (w/w) (35 kcal%) fat.
Experi mental part
Experiment 1 : Plasma CCK levels - single dose study in dog
[0026] The effect of the MTP inhibitor (+)-phenyl-(4-{4-[(4'-trifluoromethyl-biphenyl-2- carbonyl)-amino]-phenyl}-piperidin-1-yl)-acetic acid methyl ester (WO-02/20501 ) (hereinafter referred to as "compound A") on CCK plasma levels was studied in 3 groups of 8 dogs each (4 male and 4 female dogs per group). Two groups were treated orally with two different doses of compound A and one group was treated orally with the vehicle and served as a placebo group. The vehicle solution contained the same ingredients as the test formulations with omission of the test substance compound A.
[0027] The treatment groups were :
- group (1 ) treated orally with vehicle
- group (2) treated orally with 0.15 mg compound A per kg body weight - group (3) treated orally with 0.63 mg compound A per kg body weight
[0028] Dosing with either vehicle (group 1 ) or compound A (groups 2 and 3) was done together with a liquid meal at 7.00 hour for the first two males and females of each group and at 18.30 h for the last two males and females of each group. CCK plasma levels were determined before dosing, 0 hour, and at 12 and 24 hours post feeding.
[0029] As seen in Figure 1 , plasma CCK (pMol/l) expressed as the median value per group just before the meal and 12 and 24 hours after the meal showed a dose related increase of plasma CCK levels after administration of the MTP inhibiting compound A.
Experiment 2 : Plasma PYY levels - study in rats
[0030] Male Sprauge-Dawley rats (Iffa-Credo) are housed in individually ventilated cages under controlled temperature (20-240C), humidity (45-65%) and light (12-12h light/dark cycle; Lights on - 5 AM - 5PM). Rats were adapted to a semipurified casein, cornstarch and sucrose based diet (AIN-93) containing 17.5% w/w corn oil as the fat source for 10 days. The 17.5% diet is calculated to contain 35% of energy as fat.
[0031] At dark onset on day 1 1 , half the rats were switched to the same diet containing 0.02% w/w of "compound A", while the remaining rats received the control/adaptation diet. At O, 1 , 2, 4, 6, 12, 14, 16, 20 and 24 hr after diet presentation,
a group of 6 rats/treatment were killed by decapitation and 4 ml of trunk blood was collected in pre-cooled (40C) K3E plasma tubes containing protease inhibitor cocktail. Blood was centrifuged (1500 x g for 15 minutes at 40C) within 10-15 minutes of sample collection taking blood sample and stored at -7O0C until assayed.
Experiment 3 : Plasma GLP-1 levels - study in rats
[0032] Male Sprauge-Dawley rats (Iffa-Credo) are housed in individually ventilated cages under controlled temperature (20-240C), humidity (45-65%) and light (12-12h light/dark cycle; Lights on - 5 AM - 5PM). Rats were adapted to a semipurified casein, cornstarch and sucrose based diet (AIN-93) containing 17.5% w/w corn oil as the fat source for 10 days. The 17.5% diet is calculated to contain 35% of energy as fat.
[0033] At dark onset on day 1 1 , half the rats were switched to the same diet containing 0.02% w/w of "compound A", while the remaining rats received the control/adaptation diet. At 0, 1 , 2, 4, 6, 12, 14, 16, 20 and 24 hr after diet presentation, a group of 6 rats/treatment were killed by decapitation and 4 ml of trunk blood was collected in pre-cooled (40C) K3E plasma tubes containing protease inhibitor cocktail. Blood was centrifuged (1500 x g for 15 minutes at 40C) within 10-15 minutes of sample collection taking blood sample and stored at -7O0C until assayed.
Claims
Claims
I . Use of a MTP inhibiting compound for the manufacture of a medicament for the treatment of a disease mediated by increasing the levels of satiety hormones.
2. Use according to claim 1 wherein the satiety hormones are GLP-1 , PYY and CCK.
3. Use according to claim 2 wherein the satiety hormone is GLP-1.
4. Use according to claim 2 wherein the satiety hormone is PYY.
5. Use according to claim 2 wherein the satiety hormone is CCK.
6. Use of a MTP inhibiting compound for the manufacture of a medicament for increasing the levels of the satiety hormones GLP-1 , PYY and CCK and concomitant lowering of glucose levels.
7. Use of a MTP inhibiting compound for the manufacture of a medicament for increasing the levels of the satiety hormones GLP-1 , PYY and CCK and concomitant lowering of insulin sensitivity.
8. The use as claimed in claim 2 wherein the disease is cardiomyopathy.
9. The use as claimed in claim 2 wherein the disease is peripheral neuropathies.
10. The use according to any of claims 1 to 9 wherein the MTP inhibiting compound is selected from dirlotapide , N-(2,2,2-trifluoroethyl)-9-[4-[4-[[(4'-trifluoromethyl)-1 ,1 '- biphenyl^-yOcarbonyOamino^i-piperidiny^butyO-ΘH-fluorene-θ-carboxamide; (-)- [2S-[2α,4α(S*)]]-4-[4-[4-[4-[[2-(4-chlorophenyl)-2-[[(4-methyl-4H-1 !2,4-triazol-3- yl)thio]methyl]-1 ,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4- dihydro-2-(1 -methylpropyl)-3H-1 ,2,4-triazol-3-one; (+)-phenyl-(4-{4-[(4'- trifluoromethyl-biphenyl^-carbony^-aminol-phenylj-piperidin-i-y^-acetic acid methyl ester; diethyl ester[[[[3-[(dimethylamino)carbonyl]-4-[[[4'-(trifluoromethyl)- [1 ,1 '-biphenylj^-yljcarbonyljaminojphenyljacetyljoxyjmethyljphenyl propanedioic acid; [(2R)-2,3-dihydro-5-[[[6-methyl-4'-(trifluoromethyl)[1 ,1 '-biphenyl]-2-yl]- carbonyl]amino]-1 H-inden-2-yl]-carbamic acid methyl ester (WO-2000/005201 ); or
N-[2-[2-(1 H-pyrazol-1 -yl)acetyl]-2,3-dihydro-1 H-isoindol-5-yl]-2-[5- (trifluoromethyl)pyridin-2-yl]benzamide.
I 1. The use according to claim 10 wherein the MTP inhibiting compound is (-)-[2S- [2α,4α(S*)]]-4-[4-[4-[4-[[2-(4-chlorophenyl)-2-[[(4-methyl-4H-1 !2,4-triazol-3-
yl)thio]methyl]-1 ,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4- dihydro-2-(1 -methylpropyl)-3/-/-1 ,2,4-triazol-3-one.
12. The use according to claim 10 wherein the MTP inhibiting compound is
(+)-phenyl-(4-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-piperidin- 1-yl)-acetic acid methyl ester.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07101162.1 | 2007-01-25 | ||
EP07101162 | 2007-01-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008090198A1 true WO2008090198A1 (en) | 2008-07-31 |
Family
ID=38232162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/050814 WO2008090198A1 (en) | 2007-01-25 | 2008-01-24 | Use of mtp inhibitors for increasing levels of satiety hormones |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008090198A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7932268B2 (en) | 2004-03-05 | 2011-04-26 | The Trustees Of The University Of Pennsylvania | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
EP2334374A1 (en) * | 2008-08-26 | 2011-06-22 | Centocor Ortho Biotech Inc. | Stimulation of satiety hormone release |
WO2011157827A1 (en) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5712279A (en) * | 1995-02-21 | 1998-01-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
WO2000005201A1 (en) * | 1998-07-21 | 2000-02-03 | Novartis Ag | N-benzocycloalkyl-amide derivatives and their use as medicaments |
WO2000053171A1 (en) * | 1999-03-05 | 2000-09-14 | Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. | Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv |
EP1099438A2 (en) * | 1999-11-10 | 2001-05-16 | Pfizer Products Inc. | Use of APO B secretion/MTP inhibitors |
WO2002020501A2 (en) * | 2000-09-04 | 2002-03-14 | Janssen Pharmaceutica N.V. | Polyarylcarboxamides useful as lipid lowering agents |
JP2003231635A (en) * | 2002-02-06 | 2003-08-19 | Tanabe Seiyaku Co Ltd | Medicinal composition |
WO2003092694A1 (en) * | 2002-05-02 | 2003-11-13 | Pfizer Products Inc. | Treatment of diabetes and diabetic complications with nhe-1 inhibitors |
WO2004022074A1 (en) * | 2002-09-06 | 2004-03-18 | Novartis Ag | Nutritional compositions comprising a non-glucose carbohydrate or pectin and soluble fiber |
WO2004047755A2 (en) * | 2002-11-22 | 2004-06-10 | Japan Tobacco Inc. | Fused bicyclic nitrogen-containing heterocycles |
WO2005046644A1 (en) * | 2003-11-14 | 2005-05-26 | Pfizer Products Inc. | Solid amorphous dispersions of an mtp inhibitor for treatment of obesity |
WO2005070390A2 (en) * | 2004-01-21 | 2005-08-04 | Janssen Pharmaceutica N.V. | Mitratapide oral solution |
WO2006008962A1 (en) * | 2004-07-16 | 2006-01-26 | Japan Tobacco Inc. | Therapeutic or preventive drug for diabetes, obesity, or arteriosclerosis |
EP1685834A1 (en) * | 2005-01-31 | 2006-08-02 | Loders Croklaan B.V. | Use of pinolenic acid for the treatment of obesity |
US20060204567A1 (en) * | 2005-03-08 | 2006-09-14 | Jiang Hu | Potato proteinase inhibitor II exhibits activity in elevating fasting plasma cholecystokinin concentrations |
US20070093527A1 (en) * | 2005-10-18 | 2007-04-26 | Wisler Gerald L | Methods for treating disorders associated with hyperlipidemia in a mammal |
-
2008
- 2008-01-24 WO PCT/EP2008/050814 patent/WO2008090198A1/en active Application Filing
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5712279A (en) * | 1995-02-21 | 1998-01-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
WO2000005201A1 (en) * | 1998-07-21 | 2000-02-03 | Novartis Ag | N-benzocycloalkyl-amide derivatives and their use as medicaments |
WO2000053171A1 (en) * | 1999-03-05 | 2000-09-14 | Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. | Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv |
EP1099438A2 (en) * | 1999-11-10 | 2001-05-16 | Pfizer Products Inc. | Use of APO B secretion/MTP inhibitors |
WO2002020501A2 (en) * | 2000-09-04 | 2002-03-14 | Janssen Pharmaceutica N.V. | Polyarylcarboxamides useful as lipid lowering agents |
JP2003231635A (en) * | 2002-02-06 | 2003-08-19 | Tanabe Seiyaku Co Ltd | Medicinal composition |
WO2003092694A1 (en) * | 2002-05-02 | 2003-11-13 | Pfizer Products Inc. | Treatment of diabetes and diabetic complications with nhe-1 inhibitors |
WO2004022074A1 (en) * | 2002-09-06 | 2004-03-18 | Novartis Ag | Nutritional compositions comprising a non-glucose carbohydrate or pectin and soluble fiber |
WO2004047755A2 (en) * | 2002-11-22 | 2004-06-10 | Japan Tobacco Inc. | Fused bicyclic nitrogen-containing heterocycles |
WO2005046644A1 (en) * | 2003-11-14 | 2005-05-26 | Pfizer Products Inc. | Solid amorphous dispersions of an mtp inhibitor for treatment of obesity |
WO2005070390A2 (en) * | 2004-01-21 | 2005-08-04 | Janssen Pharmaceutica N.V. | Mitratapide oral solution |
WO2006008962A1 (en) * | 2004-07-16 | 2006-01-26 | Japan Tobacco Inc. | Therapeutic or preventive drug for diabetes, obesity, or arteriosclerosis |
EP1685834A1 (en) * | 2005-01-31 | 2006-08-02 | Loders Croklaan B.V. | Use of pinolenic acid for the treatment of obesity |
US20060204567A1 (en) * | 2005-03-08 | 2006-09-14 | Jiang Hu | Potato proteinase inhibitor II exhibits activity in elevating fasting plasma cholecystokinin concentrations |
US20070093527A1 (en) * | 2005-10-18 | 2007-04-26 | Wisler Gerald L | Methods for treating disorders associated with hyperlipidemia in a mammal |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9861622B2 (en) | 2004-03-05 | 2018-01-09 | The Trustees Of The University Of Pennsylvania | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
US8618135B2 (en) | 2004-03-05 | 2013-12-31 | The Trustees Of The University Of Pennsylvania | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
US9265758B2 (en) | 2004-03-05 | 2016-02-23 | The Trustees Of The University Of Pennsylvania | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
US9364470B2 (en) | 2004-03-05 | 2016-06-14 | The Trustees Of The University Of Pennsylvania | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
US9433617B1 (en) | 2004-03-05 | 2016-09-06 | The Trustees Of The University Of Pennsylvania | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
US7932268B2 (en) | 2004-03-05 | 2011-04-26 | The Trustees Of The University Of Pennsylvania | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
US10016404B2 (en) | 2004-03-05 | 2018-07-10 | The Trustees Of The University Of Pennsylvania | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
US10555938B2 (en) | 2004-03-05 | 2020-02-11 | The Trustees Of The University Of Pennsylvania | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
US11554113B2 (en) | 2004-03-05 | 2023-01-17 | The Trustees Of The University Of Pennsylvania | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
EP2334374A1 (en) * | 2008-08-26 | 2011-06-22 | Centocor Ortho Biotech Inc. | Stimulation of satiety hormone release |
EP2334374A4 (en) * | 2008-08-26 | 2011-12-28 | Janssen Biotech Inc | Stimulation of satiety hormone release |
JP2012501224A (en) * | 2008-08-26 | 2012-01-19 | ヤンセン バイオテツク,インコーポレーテツド | Stimulation of satiety hormone release |
WO2011157827A1 (en) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190314275A1 (en) | Methods and Compositions for Rectal Administration of Exenatide | |
ES2291210T3 (en) | SYNERGISTIC USE OF THIAZOLIDINDIONAS WITH PEPTIDO-1 TYPE GLUCAGONA AND ITS AGONISTS TO TREAT NON-INSULIN-DEPENDENT DIABETES. | |
Nuttall et al. | Plasma glucose and insulin response to macronutrients in nondiabetic and NIDDM subjects | |
Wu et al. | Ghrelin attenuates sepsis-induced acute lung injury and mortality in rats | |
JP4976281B2 (en) | Materials and methods for regulating metabolism | |
Drewe et al. | Role of circulating cholecystokinin in control of fat-induced inhibition of food intake in humans | |
CN102369018B (en) | Diabetes and the treatment of metabolism syndrome | |
KR20080106455A (en) | Combination treatment of metabolic disorders | |
EP2397039A1 (en) | Compositions for delaying progression of diabetes using Salacia oblonga extract | |
JP2012507558A (en) | Action mechanism of neuromedin U and its use | |
US20150290162A1 (en) | Composition and method for control of diabetes | |
Smith et al. | Type-A CCK receptors mediate the inhibition of food intake and activity by CCK-8 in 9-to 12-day-old rat pups | |
Tso et al. | Gastrointestinal Satiety Signals IV. Apolipoprotein A-IV | |
WO2008090198A1 (en) | Use of mtp inhibitors for increasing levels of satiety hormones | |
CN108451941A (en) | Treat the composition and method of diabetes | |
JP6890970B2 (en) | A composition comprising one of the HIP / PAP proteins or derivatives thereof for treating insulin resistance. | |
US20240091318A1 (en) | Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists | |
WO2024055932A1 (en) | Azacyclic compound, pharmaceutical composition thereof, and use thereof for preventing and/or treating disease | |
US20090233851A1 (en) | Insulin Resistance Improver | |
US20030105005A1 (en) | Use of a growth hormone or a growth hormone secretagogue for appetite-suppression or induction of satiety | |
US20210084956A1 (en) | Compositions and methods for hunger control and weight management | |
Metzger | Cholecystokinin: effects of duration and dose on feeding behavior, glucose and pancreatic hormones in rhesus monkeys | |
Ahmed | Role of Glucagon like peptide-1 (glp1) in health, disease and weight loss | |
Belfiore et al. | Insulin Secretion and Its Pharmacological Stimulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08708153 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08708153 Country of ref document: EP Kind code of ref document: A1 |